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Abstract: Although several viruses can easily infect the central nervous system (CNS), antiviral
drugs often show dramatic difficulties in penetrating the brain from the bloodstream since they
are substrates of active efflux transporters (AETs). These transporters, located in the physiological
barriers between blood and the CNS and in macrophage membranes, are able to recognize their
substrates and actively efflux them into the bloodstream. The active transporters currently known to
efflux antiviral drugs are P-glycoprotein (ABCB1 or P-gp or MDR1), multidrug resistance-associated
proteins (ABCC1 or MRP1, ABCC4 or MRP4, ABCC5 or MRP5), and breast cancer resistance protein
(ABCG2 or BCRP). Inhibitors of AETs may be considered, but their co-administration causes serious
unwanted effects. Nasal administration of antiviral drugs is therefore proposed in order to overcome
the aforementioned problems, but innovative devices, formulations (thermoreversible gels, polymeric
micro- and nano-particles, solid lipid microparticles, nanoemulsions), absorption enhancers (chitosan,
papaverine), and mucoadhesive agents (chitosan, polyvinilpyrrolidone) are required in order to
selectively target the antiviral drugs and, possibly, the AET inhibitors in the CNS. Moreover, several
prodrugs of antiretroviral agents can inhibit or elude the AET systems, appearing as interesting
substrates for innovative nasal formulations able to target anti-Human Immunodeficiency Virus
(HIV) agents into macrophages of the CNS, which are one of the most important HIV Sanctuaries of
the body.
Keywords: active efflux transporter; antiretroviral drug; HIV sanctuaries; thermoreversible gel;
nano-emulsion; polymeric microparticles; polymeric nanoparticles; nasal formulation; solid lipid
microparticles; virus
1. Viruses Can Have Important Neurotropic Effects
It is currently well-known that several viruses can have important neurotropic effects in infected
bodies: as an example, Canine Distemper Virus (CDV) and Measles Virus (MV) are known to
cause demyelinating disease of the central nervous system (CNS) in dogs and humans, respectively;
and Eastern Equine Encephalitis Virus (EEEV) is able to induce death or long-lasting and severe
neurological sequelae in humans [1]. Even if Vesicular Stomatitis Virus (VSV) is considered promising
as a vaccine vector, its greatest limitation is potential neurotropic activity that can be lethal within the
brain [2–4]; moreover, Herpes Simplex Virus type 1 (HSV-1) can cause potentially fatal encephalitis in
developed countries [5,6]. Finally, mice intra-nasally infected by Venezuelan Equine Encephalitis Virus
(VEEV) show a CNS phase that results in encephalitis and death [7–9].
Human Immunodeficiency Virus type-1 (HIV-1) belongs to the lentivirus family. It displays
a long latency period and a slow progressive disease culminating in severe immune deficiencies
together called acquired immune deficiency syndrome (AIDS) [10]. The virus firstly infects CD4+
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T lymphocytes, causing a severe drop in their immune effector functions. Moreover, HIV-1 shows
long-term persistence in monocytes that can easily enter the CNS across the blood–brain barrier (BBB),
where they differentiate in macrophages that are known to harbor and replicate the virus [11,12].
The presence of HIV in the brain can lead to dementia in the more severe cases [13,14]. The CNS
therefore constitutes one of the sanctuaries for HIV, from which the periphery can be re-infected and
where drug resistance is induced [11,15]. Indeed, despite the fact that antiretroviral therapies are
widely used in the treatment of AIDS and that their administration dramatically reduces viral loads
in HIV patients, the eradication of the virus from the HIV sanctuaries cannot be obtained since the
drugs are unable to reach them with therapeutic concentrations [16]. Currently, the guidelines of the
Department of Health and Human Services for the use of antiretroviral agents in adults and adolescents
living with HIV indicate several combination-based regimens using antiretroviral drugs belonging
to mechanistic classes that include nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs),
non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), a CCR5 antagonist,
such as maraviroc, or integrase inhibitors (INs), such as dolutegravir [17–20]. It is important to remark
that long-term exposure to high doses of anti-HIV drugs, in order to try to enhance their uptake in
HIV sanctuaries, can cause severe side effects, such as lipodystrophy, diabetes, and cardiovascular
disease [21].
2. Active Efflux Transporters Do Not Allow the Antiviral Drugs to Reach the Sanctuaries
of Viruses
The lack of penetration of antiretroviral drugs in the HIV sanctuaries is mainly due to the expression
of active efflux transporters (AET) on the membranes of lymphocytes [22–24], macrophages [25], and the
cells that constitute the blood−brain (BBB) and blood−cerebrospinal fluid (BCSFB) barriers [26–28].
The AET systems can be members of two transporter gene superfamilies [28–31]:
i. The ATP-binding cassette (ABC) gene family of active transporters requiring ATP hydrolysis for
their efflux activity; and
ii. The solute carrier (SLC) gene family of energy-independent or secondary active efflux transporters.
As far as antiretroviral drugs are concerned, the most studied AET systems belong to the ABC
gene family; in particular, these are P-glycoprotein (P-gp-ABCB or MDR gene family), multidrug
resistance–associated proteins (MPRs-ABCC gene family), and breast-cancer-resistance protein
(BCRP-ABCG gene family) [24,32–38].
The substrates of P-gp are amphipatic cations and organic compounds whose molecular weights
range from 200 to almost 1900 Da [24], so P-gp shows a broad substrate spectrum. MRPs transport
hydrophilic anion compounds or large molecules (MRP-1) [39] or small polar compounds (for example,
nucleosides), cyclic nucleotides, and nucleoside analogues (MRP-4, MRP-5) [40]. The substrate
specificity of BCRP appears similar to that of P-gp [27].
Table 1 reports the AET subtypes currently known to interact with antiviral drugs. It is evidenced
that the clinically approved PIs, saquinavir, ritonavir, and lopinavir, are substrates of both P-gp and
MRP-1 [24,35,37,41,42]. The antiviral drugs amprenavir, nelfinavir, indinavir (PIs), and abacavir (NRTI)
are known as P-gp substrates [43], whereas zidovudine and didanosine appear to be transported
by MRP-4 and MRP-5 [32,33,38]. Finally, zidovudine, lamivudine, abacavir, zalcitabine, stavudine,
and efavirenz appear as BCRP substrates [44], whereas ritonavir, saquinavir, and nelfinavir are
known as inhibitors of this transporter [34]. Maraviroc, a CCR5 inhibitor, is suggested to be a
P-gp substrate [45–47], whereas the IN dolutegravir appears as a P-gp and BRCP substrate [20].
Cyclosporine-A, verapamil, and mefloquine are P-gp inhibitors; some of them have been used to
define an MDR-1-specific efflux of antiviral drugs [41,48,49]. Finally, paclitaxel, probenecid, and the
leukotrienes (LT) receptor antagonist, e.g., MK-571, act as inhibitors of MRPs [38–40,50].
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Table 1. The ATP-binding cassette (ABC) efflux active transporters currently known to interact with
antiviral drugs.
Transporter Name Gene Symbol Substrates AntiviralSubstrates Inhibitors
P-glycoprotein P-gp ABCB1
amphipatic
cations and
organic
compounds
saquinavir,
ritonavir, lopinavir,
amprenavir,
nelfinavir,
indinavir, abacavir,
dolutegravir
cyclosporine-A,
verapamil,
mefloquine
Multidrug Resistance
Protein
MRP-1 ABCC1
hydrophilic
anion
compounds,
large molecules
saquinavir,
ritonavir, lopinavir
paclitaxel,
probenecid,
MK-571
MRP-4
MRP-5
ABCC4
ABCC5
small polar
compounds,
nucleoside
analogues
Zidovudine,
didanosine
Breast-Cancer-Resistance
Protein BRCP ABCG2
partially
overlap with
those of P-gp
zidovudine,
lamivudine,
abacavir,
zalcitabine,
stavudine,
efavirenz,
dolutegravir
ritonavir,
saquinavir,
nelfinavir
3. Antiviral Drugs Can Enhance the Expression of Active Efflux Transporters
It is known that exposure to xenobiotic drug substrates can enhance the expression of active efflux
transporters on brain microvascular endothelial cells. As an example, it has recently been reported
that the concomitant exposition of primary human brain microvascular endothelial cells (HBMVEC)
to HIV-1 and saquinavir induces an increased MDR-1-mediated drug efflux [51]. Moreover, it has
been demonstrated that the PIs ritonavir and atazinavir are able to induce P-gp expression in brain
microvessel endothelial cells belonging to the BBB [52–54]. These phenomena thus involve a further
restriction to the entry of antiretroviral drugs to the central nervous system.
The induction of P-gp in peripheral organs and brain microvessel endothelial cells appears to be
mediated through the activation of the nuclear pregnane X (PXR) and constitutive androstane (CAR)
receptors [55–60]. In particular, the human receptors hPXR and hCAR appear actively involved in the
regulation of P-gp expression in the human brain microvessel endothelial cell culture system [61]. A few
PIs, such as ritonavir, amprenavir, and lopinavir, are known to be hPXR ligands or activators [62,63].
Recently, in vitro studies performed on human brain microvessels endothelial cells hCMEC/D3
demonstrated that amprenavir, atazanavir, efavirenz, ritonavir, and lopinavir activate hPXR, whereas
abacavir, efavirenz, and nepvirapine activate hCAR. Moreover, these drugs appear to be able to
increase P-gp expression in hCMEC/D3 cells [64]. In other words, a great number of PIs are hPXR
ligands: abacavir and nevirapine are hCAR ligands, and efavirenz is a ligand of both PXR and hCAR.
These data suggest that the nuclear receptor activity of these ligands can further restrict their ability
to enter the brain, being able to increase P-gp expression at the BBB level. Taking these aspects into
account, it has been suggested that the targeted suppression of P-gp expression in the HIV-1-infected
reservoirs of the body may constitute a new strategy able to inhibit antiretroviral drug efflux from the
brain [51].
4. AET Inhibitors: Promising in Vitro Results Not Confirmed by Clinical Trials
The first AET inhibitors were discovered about 30 years ago when the enhancement of the
cytotoxicity of some anticancer drugs induced by verapamil (a vasodilator) and cyclosporin A
(an immunosuppressant) was revealed. These drugs were indeed able to reverse the overexpression
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effects of P-gp. However, an important obstacle related to this type of inhibitor was the very high
concentration required to inhibit P-gp, since they were not specifically designed to be inhibitors of
efflux transporters. The high concentrations of inhibitors induced severe unwanted effects when their
distribution was ubiquitous in the body. As a consequence, this “first-generation” of inhibitors could
not be used in clinical trials [65,66]. Analogs of first-generation inhibitors were obtained as a “second
generation” of inhibitors (such as valspodar), which were characterized by higher inhibitory activity
and the absence of therapeutic targets other than the targeted transporters. However, also in this
case, patients suffered severe unwanted side effects following their administration, which were likely
due to their pharmacokinetic interactions with the drugs [28,65–67]. Finally, a “third generation” of
AET inhibitors (such astariquidar, zosuquidar, and laniquidar), which was characterized by very high
potency and the absence of drug metabolic interactions, was not confirmed as being deprived of severe
unwanted effects when administered to patients, probably as a result of their ubiquitous activity on
the cells of the body [28,65–67].
5. Prodrugs of Antiviral Drugs: New Proposals against the AET Activity
Taking into account the difficulties related to the clinical use of ABC transporter inhibitors,
the design of prodrugs able to elude the transporters would appear to be a promising solution to
this problem. Moreover, new formulations able to target the drugs in the CNS bypassing the BBB
are emerging. The loading of ABC transporter inhibitors in this last type of formulation could open
interesting perspectives for the selective target of their action within the central nervous system [28].
Knowledge of the structure–activity relationships (SAR) of ABC efflux pumps should be necessary
for a prodrug approach, but, in general, the AET systems are characterized by multiple binding sites
and do not interact with their substrates in a lock-and-key manner, so their activity cannot be readily
evaluated by classic Michaelis–Menten kinetics [27,68]. A first SAR approach in order to obtain antiviral
prodrugs able to inhibit AET efflux activity was proposed by Namanja and co-workers [26] on the
basis of the solved crystal structure of mouse P-gp [69]. Taking into account that P-gp shows a large
and fluid binding cavity, the HIV reverse transcriptase inhibitor abacavir was converted into a dimeric
prodrug able to act as a potent P-gp inhibitor and revert to the monomeric form upon entry into cells
overexpressing the efflux transporter. The tether length between the abacavir molecules in the prodrug
dimers was able to modulate their inhibitory potency in two different cell lines, in particular, a human
brain capillary endothelial cell line expressing endogenous levels of P-gp and a P-gp overexpressing
CD4+ T-lymphocyte cell line [70]. The approach of dimeric prodrugs as AET inhibitors could be
interesting, as selective targeting of the prodrugs may be obtained in the central nervous system where
it seems reasonable to hypothesize they can easily reach therapeutic concentrations in the cells acting
as HIV reservoirs.
Recently, we proposed a new prodrug strategy of antiviral drugs demonstrating that the ester
conjugation of zidovudine (AZT) with ursodeoxycholic acid, a bile acid which can permeate the CNS,
results in a prodrug (UDCA–AZT) able to elude the AET transporters whose AZT is a substrate in
cell monolayers showing epithelial barrier features [71]. In particular, this type of prodrug was not
effluxed from cell monolayers able to efflux AZT, but, at the same time, the activity of the transporters
was not inhibited by the prodrug itself [71]. These data suggest that the conjugation of antiviral drugs
with bile acids may constitute a new strategy in order to elude, without inhibiting, the AET systems
that normally preclude the entry of the antiretroviral drugs in HIV sanctuaries. In this regard, we have
very recently confirmed that UDCA–AZT is able to permeate and remain in murine macrophages with
an efficiency which is twenty times higher than that of AZT [25]. Moreover, the prodrug, obtained
by conjugation of AZT with UDCA, appeared to be suitable for loading in both polymeric micro- or
nano-spheres and solid lipid microparticles [25,72,73] used as innovative formulations to target the
prodrug in the central nervous system following their nasal administration. The aspects regarding
brain targeting following nasal administration of antiviral drugs or their prodrugs will be discussed in
the following sections.
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6. Micro- and Nano-Particulate Systems: Can These Innovative Formulations Target the Antiviral
Drugs in the Central Nervous System?
Bearing in mind that monocytes and macrophages can act as Trojan Horses for all members of
the lentivus family (thus inducing the entry of HIV into its sanctuaries), using the migratory ability
of these cells has been proposed in order to carry the antiretroviral drugs to the central nervous
system [74]. In particular, the idea of formulating nanoparticles loaded with an antiretroviral drug has
been developed in order to obtain their efficient takeup by macrophages, that following intravenous
administration, should migrate to the HIV-infected tissues and release the antiretroviral drug. In this
regard, it has been reported that indinavir (IDV)-loaded nanoparticles, obtained by coating an IDV
suspension, prepared by high-pressure homogenization, with Lipoid E80, were efficiently uptaken by
virus infected macrophages. The loaded nanoparticles were able to suppress virus replication for a long
period of time in the macrophages [75]. The intravenous administration of macrophages containing the
nanoparticles were shown to migrate to the lung, spleen, liver, and lymph nodes, where they induced
strong antiretroviral activities [76]. As far as the CNS was concerned, other strategies to target the
antiviral drugs appeared to be more suitable.
7. Nasal Administration: A Promising Strategy for Antiviral Drug Uptake in the Brain
Receptor-mediated transportation, transporter-mediated transport, adsorptive-mediated
transportation, or temporarily increased BBB permeability represent several important strategies
currently studied in order to obtain the uptake of drugs in the CNS. Receptor-mediated transportation
is based on the binding of specific receptors of BBB by ligands able to mediate their internalization
into cells. This strategy is often related to high costs of formulation [77].
Transporter-mediated transport is based on the conjugation of drugs with nutritive material
molecules that can be recognized and taken up in the CNS by specific transporters overexpressed
in the BBB. Unfortunately, several conjugates may not be taken up even if they are recognized by
the transporters [78]. Adsorptive-mediated transportation is based on the use of cationic proteins
and peptides which can interact with negatively charged BBB. This strategy is, however, affected by
poor selectivity toward the CNS [77]. A temporary opening of the BBB can be obtained by chemical
compounds able to enhance BBB permeability or by receptor-involved changing of tight junctions; in
this case, well-optimized protocols are needed [77].
In order to obtain the uptake of antiviral drugs in the central nervous system, the nasal approach
would appear to be a promising strategy, as it is potentially able to deliver drugs directly into the CNS
from the nasal cavity [77]. Intranasal delivery was indeed discovered about 30 years ago as a new
method for delivery of drugs to the CNS [74]. Currently, it is well-known that after nasal application,
a drug-escaping mucociliary clearance and enzymatic degradation can permeate not only into the
bloodstream, but also into the cerebrospinal fluid (CSF) or the brain tissue across the olfactory region
or via the trigeminal pathway of the nasal cavity [79,80]. There are three known pathways allowing
the drug access to the brain or CSF from the nasal cavity: (i) the olfactory pathway (direct paracellular
or transcellular transport via the olfactory neurones or olfactory epithelial cells); (ii) the trigeminal
pathway (transport via trigeminal nerves); and (iii) the systemic pathway (the drug is absorbed into
the bloodstream, then it has the ability to cross the BBB) [81]. The last of these pathways appears
to have the poorest chances of allowing antiviral drugs access to the central nervous system, since
most of them are substrates of the AET systems expressed in the BBB. In contrast, the olfactory and
trigeminal pathways seem to offer better chances of the antiviral drugs being targeted in the brain.
It is indeed known that drug delivery from the nose to the CNS along these pathways can occur
within a few minutes by an extracellular route without binding to any receptor or undergoing axonal
transport [82]. Some drugs can be axonally transported into the brain after endocytosis, but this
process generally requires a few days [74]. The olfactory neural pathway allows for distribution of
the drugs in the olfactory bulb, anterior olfactory nucleus, frontal cortex, and hippocampus (rostral
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brain structures); the trigeminal pathway allows for drug distribution in the upper cervical spinal cord,
midbrain, pons, and hypothalamus (caudal brain structures) [79].
The efficacy of nasal administration against neurotropic viral effects was tested on mice infected
by herpes simplex virus type 1 (HSV-1). In particular, mice models of HSV-1 encephalitis received an
intranasal pretreatment with the immunostimulant polyinosinic:polycytidylic acid (poly I:C) using a
saline vehicle, and they showed a significantly higher mean life expectancy and an increased rate of
survival than mice with an intraperitoneal pretreatment of poly I:C [83].
The nasal administration of a water solution of ribavirin, a nucleoside analogue able to inhibit the
canine distemper virus (CDV) and also indicated for treatment of hepatitis C [84], allowed investigators
to obtain drug concentrations in the olfactory bulb of rats similar to those obtained after intravenous
administration, whereas the nasal administration of the raw solid drug, using a specific Dry-Powder
Insufflator designed to produce a puff of fine powder, led to significantly higher levels [85]. This result
allows us to hypothesize that formulations able to increase the contact between the drug and olfactory
nasal mucosa may induce an enhancement of drug bioavailability in the brain. Very recently, a powder
formulation of agglomerates constituted by micronized ribavirin and α-cyclodextrin spray-dried
microparticles was nasally administered to rats. Ribavirin accumulation in the brain obtained by this
formulation was higher than that obtained by nasal administration of ribavirin-micronized powder
in the absence of α-cyclodextrin microparticles able to induce penetration-enhancing properties [86].
Appropriate strategies therefore appear necessary for both formulations and devices in order to
optimize drug uptake in the CNS after nasal administration.
8. What Strategies Are Currently Related to Nasal Administration of Antiviral Drugs?
It is important to underline that effective brain uptake requires special devices and nasal
formulations able to induce drug deposition in the olfactory region of the nose, prolonged residence
time, and high local drug concentration for diffusion. Several strategies appear necessary in
order to optimize brain delivery of drugs by intranasal administration, such as the addition of
penetration enhancers or mucoadhesive materials or the preparation of micro- and nano-particulate
formulations [87].
8.1. An Innovative Device for the Nasal Administration of Antiviral Drugs
Many devices for nasal administration are known, even if not all appear to be suitable for specific
deposition of drug amounts in the olfactory region of the nasal cavity. As an example, spray pumps,
drops and syringes with tubes, or a vortical flow atomizer are not recommended for nose-to-brain
delivery of drugs, whereas appropriate pressurized metered dose inhalers are designed for this
purpose. Recently, a bidirectional breath-powered nasal delivery platform was proposed in order to
optimize the deposition of drugs in the nasal cavity and nose-to-brain delivery while overcoming
unwanted pulmonary distribution [88–90]. Concerning innovative devices for the nasal administration
of antiviral drugs, a pressurized olfactory delivery (POD) aerosol was developed in order to induce
the deposition of a greater amount of drugs into the olfactory region of the nasal cavity in rats [88].
Two model drugs, mannitol and relfinavir, were chosen in order to compare their brain and blood
levels after nasal administration of nose drops in rats, which deposited primarily on the respiratory
region, or after deposition primarily on their olfactory region with a POD. The cortex-to-blood ratio
increased about 4- and 16-fold for mannitol and relfinavir, respectively, with POD administrations
compared to those with nose drops. This result confirms that an efficient and selective deposition of
drugs on the olfactory region of the nasal cavity induces efficacious direct nose-to-brain transport [88].
8.2. Design of Innovative Nasal Formulations for Antiviral Drugs
Currently, the clinical nasal formulations involving antiviral effects appear to be focused
on vaccines [91] or on treatments against cold viruses acting outside of the central nervous
system [92]. Innovative formulations able to target antiviral drugs in the CNS are therefore
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needed. Regarding studies on innovative nasal formulations, the development of antiretroviral
efavirenz (EFV)-loaded nanoparticles based on poly(ε-caprolactone) (PCL), Eudragit® RS 100
(RS, a copolymer of ethylacrylate, methylmethacrylate, and methacrylic acid esterified with quaternary
ammonium groups), and their blends has been proposed [93]. The nanoparticles were obtained by
nanoprecipitation or emulsion/solvent diffusion/evaporation, and nanoprecipitation was shown to
result in smaller particles and narrower size distribution patterns, even if all of the systems displayed
a remarkably high encapsulation efficiency and drug payload regardless of the polymer composition
and the production technique. The poly(methacrylate)’s presence in formulation procedures allowed
for a fine tuning of the particle size and the release kinetics; moreover, the incorporation of
poly(methacrylate) induced strongly positive Z-potential values of the nanoparticles [93]. This property
should induce mucoadesive properties in the nanoparticles with a likely improvement in their residence
time in contact with the nasal mucosa. It is indeed well-known that the presence of positive charges
induces mucoadhesive properties in polymers, since the mucosal membranes are characterized by the
presence of negatively charged species [94].
It is important to remark that an efficient nasal formulation should be able to prolong the residence
time within the nasal cavity in order to enhance the bioavailability of the drug. This goal can be
achieved with the use of “intelligent” polymers, which may respond to nasal cavity temperature [95]
or pH [96], or which can show mucoadhesive properties that enhance the adhesion of formulations
onto nasal mucosa [97] and drug bioavailability [98].
Thermoresponsive and mucoadhesive hydrogel formulations based on the thermosensitive
polymer Pluronic® 127 and either carboxymethyl cellulose or chitosan were studied in vitro as
intranasal sprays in order to optimize their deposition in the nasal cavity, their gel transition at 34 ◦C
(the nasal cavity temperature), and the release profiles of adamantine chosen as a model drug [99].
Studies performed using an in vitro human nasal airway model evidenced that chitosan can provide
the requirements for mucoadhesion in these formulations [99].
Chitosan is a cationic polysaccharide obtained from the deacetylation of chitin, a polymer
abundant in cretaceous organisms. Chitosan is currently known for its biocompatibility,
biodegradability, and low toxicity, and is therefore used in several pharmaceutical applications [100].
Chitosan appears to be promising for nasal delivery, as it is able to bind to the nasal mucosal membrane
inducing an increase in the retention time of formulations which contain it. Indeed, the positively
charged amino groups of chitosan effectively interact with the anionic groups of the mucous layers [81].
Moreover, chitosan appears to be a good absorption enhancer, as it is able to transiently open the tight
junctions in the epithelial cells [101]. These properties allow chitosan to prolong the residence time of a
formulation in the nasal cavity and, at the same time, to enhance drug permeation across the mucosal
membranes [81].
Among the biocompatible polymers, poly-N-vinyl-2-pyrrolidone (PVP) shows a wide range of
pharmaceutical applications as a hydrogel, including in nasal formulations [102]. Blends of PVP and
polyethylene glycol (PEG) 600 show adhesive properties [103].
Polymeric mucoadhesive hydrogels based on PVP or chitosan have been studied as nasal delivery
formulations for acyclovir. In particular, the muco-adhesivity was studied in the nasal mucosal tissue
of sheep by evaluating the force required to detach the formulations from the mucosa. The most
mucoadhesive formulations were shown to be chitosan gel and PVP in the presence of PRG 600.
Higher release rates were evidenced by PVP compared to chitosan gels [104].
In addition to chitosan, papaverine (a phosphodiesterase inhibitor) has also been considered
for its action on tight junctions of nasal mucosa. In particular, after intranasal administration to
rats, papaverine appeared to be able to induce a rapid and transient decrease in the tight junction
protein-phosphorylated occludin in the olfactory epithelium. This phenomenon was associated with
an approximately four-fold increase in the amounts of gemcitabine (chosen as a model drug) reaching
the brain, which was explained by transient dephosphorylation of occludin following disassembly of
the tight junctions in the cytoplasm of mucosal cells [105].
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8.3. Nasal Formulations and Brain Targeting of Antiviral Drugs
New nasal formulations of antiviral drugs have been administered in vivo in order to evaluate
drug absorption in the central nervous system. Among these, an intranasal nano-emulsion based on
the hydrophobic oil Capmul MCM, in the presence of Tween 80 and PEG 400 as surfactant and
co-surfactant, respectively, was developed for brain targeting of saquinavir mesylate. This type
of formulation was able to induce a higher concentration of the drug in the brain after intranasal
administration compared to saquinavir amounts obtained after intravenous administration of plain
drug suspension. In particular, the drug targeting efficacy (DTE) and nose-to-brain drug direct transport
percentage (DTP) values obtained by nasal administration of the nano-emulsion were 2919 and 97,
respectively, indicating the efficacy of this formulation in promoting the nose-to-brain delivery of
saquinavir mesylate [106].
8.3.1. Nasal Formulations for Zidovudine Administration
Several nasal formulations have been studied in order to induce the uptake of zidovudine (AZT)
in the central nervous system. It is well-known that AZT penetration in the CNS is poor because it is a
substrate of AET systems expressed by both the BBB and BCSFB [107–109]. The AET systems induce,
in vivo, an asymmetric transport of AZT across these barriers, where the rate of AZT efflux from the
CNS to blood is greater than its influx rate [110], resulting in a poor CNS/plasma ratio (about 0.1) of
zidovudine [111]. It is important to underline that AZT activity in the CNS is of great importance in
those CSF subarachnoid spaces that contain macrophages constituting the only site of HIV replication
in the brain [112,113]. The presence of AET systems in macrophage membranes [25] can constitute a
further obstacle for AZT penetration in these cells. Significantly high concentrations of AZT therefore
appear necessary in the bloodstream in order to allow the drug to reach and maintain a minimum
effective concentration in the CNS. The intravenous administration of high doses of AZT allowed
its detection in the CSF of rats [114], a phenomenon probably due to the saturation of AET systems.
Indeed, the AZT amounts detected in the CSF increased when AZT was intravenously co-administered
with probenecid [114], even if it is known that the concomitant presence of high hematic AZT and AET
inhibitor concentrations cause severe unwanted effects [27,115].
The first studies on nasal administration of zidovudine to rats were performed using formulations
constituted by an aqueous suspension of AZT (20 µmol/kg) or a suspension of AZT and
probenecid [114]. Following nasal administration, AZT showed rapid absorption in the bloodstream
and the CSF, even if the CSF/plasma ratio was lower than 1 and weakly increased in the presence of
probenecid [114].
A thermoreversible gel, based on Poloxamer 407 (thermoreversible gelling agent) and n-tridecyl-β-
D-maltoside (permeation enhancer), was prepared as a nasal formulation of AZT. Doses of 1 mg/kg
AZT nasally administered to rabbits led to sensibly higher CSF concentrations of AZT than those
obtained by intravenous administration. In particular, the drug targeting efficacy (DTE) and
nose-to-brain drug direct transport percentage (DTP) values were 11.51 and 99.27, respectively.
Moreover, following the nasal administration of the thermoreversible gel, the CSF/plasma ratio
values of AZT were >1 and showed DTE and DTP values of 139.15 and 99.48, respectively [116,117].
These data evidence the importance of appropriate nasal formulations in order to promote the antiviral
target in the CNS.
8.3.2. Nasal Formulations for the Administration of a Prodrug of Zidovudine
Recently, the prodrug UDCA-AZT, obtained by means of ester conjugation of zidovudine with
ursodeoxycholic acid [71], was loaded in micro-particulate nasal formulations. This prodrug is
characterized by its ability to elude the AET systems [71], so it appears to be promising in order
to prolong its permanence upon targeting in the central nervous system and to permeate in its
macrophages where the AZT activity is required against HIV. We have indeed demonstrated that
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UDCA-AZT is able to permeate and remain in murine macrophages with an efficiency twenty times
higher than that of AZT [25].
Microparticles based on stearic acid were loaded with UDCA-AZT and nasally administered to
rats in doses of 800 µg/Kg. The microparticles induced a significant increase of the dissolution rate
of the free prodrug, allowing for an efficient uptake in the CSF of rats, but not in the bloodstream,
demonstrating the existence of a direct nose—CNS pathway for UDCA-AZT. In the presence of
chitosan, the CSF prodrug uptake induced by the stearic acid microparticles increased six times, up to
1.5 µg/mL within 150 min after nasal administration [73]. Taking into account chitosan’s ability to
promote UDCA-AZT uptake in the CNS after nasal administration, a new nasal formulation was
prepared where the prodrug was encapsulated in chitosan chloride microparticles. In this case too,
a selective uptake of UDCA-AZT was obtained, showing concentrations of up to 3 µg/mL in the CSF,
where the prodrug can act as an AZT carrier in macrophages [25].
8.3.3. Can Nasal Administration of Insulin be Useful against AIDS Neurotoxicity?
Very recently, it has been demonstrated that insulin treatment of HIV-infected microglia cultures
induces a reduction in viral replication as evidenced by the suppression of supernatant HIV-1 p24
levels and by the reduction of CXCL10 and IL-6 transcript levels. Moreover, it has been demonstrated
that primary human neurons treated with insulin prevent HIV-1 Vpr-mediated cell process retraction
and death. Bearing these aspects in mind, feline immunodeficiency virus (FIV)-infected animals
were treated by intranasal insulin and showed reduced CXCL10, IL-6, and FIV RNA levels in brain
in comparison with control infected animals. Moreover, nasal administration of insulin allowed
for the improvement of neurobehavioral performance in FIV-infected animals, such as motor and
memory performances [118]. These data suggest that nasal administration of insulin may represent
a new therapeutic option for patients affected by neurodegenerative syndrome HIV-associated
neurocognitive disorders.
9. Conclusions
We have evidenced that several viruses can easily infect the central nervous system, but even if
numerous antiviral therapies can be efficacious at peripheral levels, they appear to be inefficacious
at the central level, since the antiviral drug substrates of the active efflux transporters (AET) are
expressed by the BBB and macrophages. Exposure of the body to antiviral drugs can further increase
the expression of these transporters with a consequent further reduction in the antiviral efficacy in
the central nervous system. In order to counteract this phenomenon, the use of AET inhibitors is not
allowed in clinical trials, because these inhibitors induce severe unwanted effects when not selectively
targeted in specific action sites of drugs. As a consequence, innovative devices and formulations are
required in order to selectively target the antiviral drugs and, possibly, the AET inhibitors in the CNS.
Several prodrugs of antiviral drugs appear able to inhibit or elude the AET systems, so they would
appear to be interesting substrates for innovative formulations. The nasal approach seems to offer a
direct nose-to-brain pathway for antiviral drugs. Appropriate devices and formulations, implemented
with absorption enhancers, have been designed and administered in order to target the antiviral drugs
or their prodrugs in the central nervous system. The results obtained from these studies indicate that
the “nasal” strategy is a promising means to promote the efficacy of antiviral therapies against the
neurotoxicity of viruses.
Acknowledgments: Support from the University of Ferrara (F72I15000470005) in the frame of the project FAR2014
is gratefully acknowledged.
Author Contributions: Alessandro Dalpiaz wrote the paper and Barbara Pavan read and corrected critically
the paper.
Conflicts of Interest: The authors declare no conflict of interest.
Pharmaceutics 2018, 10, 39 10 of 15
References
1. Calisher, C.H. Medically important arboviruses of the United States and Canada. Clin. Microbiol. Rev. 1994, 7,
89–116. [CrossRef] [PubMed]
2. Huneycutt, B.S.; Bi, Z.; Aoki, C.J.; Reiss, C.S. Central neuropathogenesis of vesicular stomatitis virus infection
of immunodeficient mice. J. Virol. 1993, 67, 6698–6706. [PubMed]
3. Van den Pol, A.N.; Dalton, K.P.; Rose, J.K. Relative neurotropism of a recombinant rhabdovirus expressing a
green fluorescent envelope glycoprotein. J. Virol. 2002, 76, 1309–1327. [CrossRef] [PubMed]
4. Van den Pol, A.N.; Davis, J.N. Highly attenuated recombinant vesicular stomatitis virus VSV-12’GFP displays
immunogenic and oncolytic activity. J. Virol. 2013, 87, 1019–1034. [CrossRef] [PubMed]
5. Tyler, K.L. Update on herpes simplex encephalitis. Rev. Neurol. Dis. 2004, 1, 169–178. [PubMed]
6. Whitley, R.J.; Kimberlin, D.W. Herpes simplex encephalitis: Children and adolescents. Semin. Pediatr. Infect. Dis.
2005, 16, 17–23. [CrossRef] [PubMed]
7. Aronson, J.F.; Grieder, F.B.; Davis, N.L.; Charles, P.C.; Knott, T.; Brown, K.; Johnston, R.E. A single-site mutant
and revertants arising in vivo define early steps in the pathogenesis of Venezuelan equine encephalitis virus.
Virology 2000, 270, 111–123. [CrossRef] [PubMed]
8. Charles, P.C.; Trgovcich, J.; Davis, N.L.; Johnston, R.E. Immunopathogenesis and immune modulation of
Venezuelan equine encephalitis virus-induced disease in the mouse. Virology 2001, 284, 190–202. [CrossRef]
[PubMed]
9. Davis, N.L.; Grieder, F.B.; Smith, J.F.; Greenwald, G.F.; Valenski, M.L.; Sellon, D.C.; Charles, P.C.; Johnston, R.E.
A molecular genetic approach to the study of Venezuelan equine encephalitis virus pathogenesis. Arch. Virol.
Suppl. 1994, 9, 99–109. [PubMed]
10. Pomerantz, R.J. Reservoirs, sanctuaries and residual disease: The hiding spots of HIV-1. HIV Clin. Trials
2003, 4, 137–143. [CrossRef] [PubMed]
11. Lambotte, O.; Deiva, K.; Tardieu, M. HIV-1 persistence, viral reservoir and the central nervous system in the
HAART era. Brain Pathol. 2003, 13, 95–103. [CrossRef] [PubMed]
12. Aquaro, S.; Svicher, V.; Schols, D.; Pollicita, M.; Antinori, A.; Balzarini, J.; Perno, C.F. Mechanisms underlying
activity of antiretroviral drugs in HIV-1-infected macrophages: New therapeutic strategies. J. Leukoc. Biol.
2006, 80, 1103–1110. [CrossRef] [PubMed]
13. Kaul, M. HIV’s double strike at the brain: Neuronal toxicity and compromised neurogenesis. Front. Biosci.
2008, 13, 2484–2494. [CrossRef] [PubMed]
14. Kolson, D.L.; Gonzalez-Scarano, F. HIV and HIV dementia. J. Clin. Investig. 2000, 106, 11–13. [CrossRef]
[PubMed]
15. Cunningham, P.H.; Smith, D.G.; Satchell, C.; Cooper, D.A.; Brew, B. Evidence for independent development
of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid. AIDS 2000, 14, 1949–1954.
[CrossRef] [PubMed]
16. Gray, F.; Scaravilli, F.; Everall, I.; Chretien, F.; An, S.; Boche, D.; Adle-Biassette, H.; Wingertsmann, L.;
Durigon, M.; Hurtrel, B.; et al. Neuropathology of early HIV-1 infection. Brain Pathol. 1996, 6, 1–15.
[CrossRef] [PubMed]
17. Panel on Antiretroviral Guidelines for Adults and Adolescents (2017). Guidelines for the Use of Antiretroviral
Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services. Available
online: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed on 21 March 2018).
18. Moore, J.P.; Kitchen, S.G.; Pugach, P.; Zack, J.A. The CCR5 and CXCR4 coreceptors—Central to understanding
the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res. Hum.
Retroviruses 2004, 20, 111–126. [CrossRef] [PubMed]
19. Dorr, P.; Westby, M.; Dobbs, S.; Griffin, P.; Irvine, B.; Macartney, M.; Mori, J.; Rickett, G.; Smith-Burchnell, C.;
Napier, C.; et al. Maraviroc (UK-427, 857), a potent, orally bioavailable, and selective small-molecule inhibitor
of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
Antimicrob. Agents Chemother. 2005, 49, 4721–4732. [CrossRef] [PubMed]
20. Reese, M.J.; Savina, P.M.; Generaux, G.T.; Tracey, H.; Humphreys, J.E.; Kanaoka, E.; Webster, L.O.;
Harmon, K.A.; Clarke, J.D.; Polli, J.W. In vitro investigations into the roles of drug transporters and
metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
Drug Metab. Dispos. 2013, 41, 353–361. [CrossRef] [PubMed]
Pharmaceutics 2018, 10, 39 11 of 15
21. Boyd, M.; Reiss, P. The long-term consequences of antiretroviral therapy: A review. J. HIV Ther. 2006, 11,
26–35. [PubMed]
22. Chaudhary, P.M.; Mechetner, E.B.; Roninson, I.B. Expression and activity of the multidrug resistance
P-glycoprotein in human peripheral blood lymphocytes. Blood 1992, 80, 2735–2739. [PubMed]
23. Neyfakh, A.A.; Serpinskaya, A.S.; Chervonsky, A.V.; Apasov, S.G.; Kazarov, A.R. Multidrug-resistance
phenotype of a subpopulation of T-lymphocytes without drug selection. Exp. Cell Res. 1989, 185, 496–505.
[CrossRef]
24. Janneh, O.; Jones, E.; Chandler, B.; Owen, A.; Khoo, S.H. Inhibition of P-glycoprotein and multidrug
resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells
and primary human lymphocytes. J. Antimicrob. Chemother. 2007, 60, 987–993. [CrossRef] [PubMed]
25. Dalpiaz, A.; Fogagnolo, M.; Ferraro, L.; Capuzzo, A.; Pavan, B.; Rassu, G.; Salis, A.; Giunchedi, P.; Gavini, E.
Nasal chitosan microparticles target a zidovudine prodrug to brain HIV sanctuaries. Antivir. Res. 2015, 123,
146–157. [CrossRef] [PubMed]
26. Namanja, H.A.; Emmert, D.; Davis, D.A.; Campos, C.; Miller, D.S.; Hrycyna, C.A.; Chmielewski, J. Toward
eradicating HIV reservoirs in the brain: Inhibiting P-glycoprotein at the blood-brain barrier with prodrug
abacavir dimers. J. Am. Chem. Soc. 2012, 134, 2976–2980. [CrossRef] [PubMed]
27. Pavan, B.; Dalpiaz, A. Prodrugs and endogenous transporters: Are they suitable tools for drug targeting into
the central nervous system? Curr. Pharm. Des. 2011, 17, 3560–3576. [CrossRef] [PubMed]
28. Pavan, B.; Paganetto, G.; Rossi, D.; Dalpiaz, A. Multidrug resistance in cancer or inefficacy of neuroactive agents:
Innovative strategies to inhibit or circumvent the active efflux transporters selectively. Drug Discov. Today 2014, 19,
1563–1571. [CrossRef] [PubMed]
29. Pardridge, W.M. The blood–Brain barrier: Bottleneck in brain drug development. NeuroRX 2005, 2, 3–14.
[CrossRef] [PubMed]
30. Pardridge, W.M. Blood–Brain barrier delivery. Drug Discov. Today 2007, 12, 54–61. [CrossRef] [PubMed]
31. Pardridge, W.M. Drug targeting to the brain. Pharm. Res. 2007, 24, 1733–1744. [CrossRef] [PubMed]
32. Wijnholds, J.; Mol, C.A.; van Deemter, L.; de Haas, M.; Scheffer, G.L.; Baas, F.; Beijnen, J.H.; Scheper, R.J.;
Hatse, S.; De Clercq, E.; et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able
to transport nucleotide analogs. Proc. Natl. Acad. Sci. USA 2000, 97, 7476–7481. [CrossRef] [PubMed]
33. Jorajuria, S.; Dereuddre-Bosquet, N.; Becher, F.; Martin, S.; Porcheray, F.; Garrigues, A.; Mabondzo, A.;
Benech, H.; Grassi, J.; Orlowski, S.; et al. ATP binding cassette multidrug transporters limit the anti-HIV
activity of zidovudine and indinavir in infected human macrophages. Antivir. Ther. 2004, 9, 519–528.
[PubMed]
34. Gupta, A.; Zhang, Y.; Unadkat, J.D.; Mao, Q. HIV protease inhibitors are inhibitors but not substrates of
the human breast cancer resistance protein (BCRP/ABCG2). J. Pharmacol. Exp. Ther. 2004, 310, 334–341.
[CrossRef] [PubMed]
35. Ronaldson, P.T.; Lee, G.; Dallas, S.; Bendayan, R. Involvement of P-glycoprotein in the transport of saquinavir
and indinavir in rat brain microvessel endothelial and microglia cell lines. Pharm. Res. 2004, 21, 811–818.
[CrossRef] [PubMed]
36. Park, S.; Sinko, P.J. P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of
saquinavir in mice. J. Pharmacol. Exp. Ther. 2005, 312, 1249–1256. [CrossRef] [PubMed]
37. Bachmeier, C.J.; Spitzenberger, T.J.; Elmquist, W.F.; Miller, D.W. Quantitative assessment of HIV-1 protease
inhibitor interactions with drug efflux transporters in the blood-brain barrier. Pharm. Res. 2005, 22, 1259–1268.
[CrossRef] [PubMed]
38. Eilers, M.; Roy, U.; Mondal, D. MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and
zidovudine, from human endothelial cells. Exp. Biol. Med. 2008, 233, 1149–1160. [CrossRef] [PubMed]
39. Dallas, S.; Miller, D.S.; Bendayan, R. Multidrug resistance-associated proteins: Expression and function in
the central nervous system. Pharmacol. Rev. 2006, 58, 140–161. [CrossRef] [PubMed]
40. Sampath, J.; Adachi, M.; Hatse, S.; Naesens, L.; Balzarini, J.; Flatley, R.M.; Matherly, L.H.; Schuetz, J.D. Role of
MRP4 and MRP5 in biology and chemotherapy. AAPS Pharm. Sci. 2002, 4, E14. [CrossRef] [PubMed]
41. Janneh, O.; Owen, A.; Chandler, B.; Hartkoorn, R.C.; Hart, C.A.; Bray, P.G.; Ward, S.A.; Back, D.J.; Khoo, S.H.
Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by
inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS 2005, 19, 2097–2102. [CrossRef] [PubMed]
Pharmaceutics 2018, 10, 39 12 of 15
42. Meaden, E.R.; Hoggard, P.G.; Newton, P.; Tjia, J.F.; Aldam, D.; Cornforth, D.; Lloyd, J.; Williams, I.; Back, D.J.;
Khoo, S.H. P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in
HIV-infected individuals. J. Antimicrob. Chemother. 2002, 50, 583–588. [CrossRef] [PubMed]
43. Varatharajan, L.; Thomas, S.A. The transport of anti-HIV drugs across blood–CNS interfaces: Summary of
current knowledge and recommendations for further research. Antiv. Res. 2009, 82, A99–A109. [CrossRef]
[PubMed]
44. Sosnik, A. Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing
“Generally Recognized As Safe” (GRAS) nanopharmaceuticals: A review. Adv. Drug Deliv. Rev. 2013, 65,
1828–1851. [CrossRef] [PubMed]
45. Walker, D.K.; Abel, S.; Comby, P.; Muirhead, G.J.; Nedderman, A.N.; Smith, D.A. Species differences in the
disposition of the CCR5 antagonist, UK-427, 857, a new potential treatment for HIV. Drug Metab. Dispos.
2005, 33, 587–595. [CrossRef] [PubMed]
46. Walker, D.K.; Bowers, S.J.; Mitchell, R.J.; Potchoiba, M.J.; Schroeder, C.M.; Small, H.F. Preclinical assessment
of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the
central nervous system (CNS) and gut-associated lymphoid tissue (GALT). Xenobiotica 2008, 38, 1330–1339.
[CrossRef] [PubMed]
47. Ramanathan, S.; Abel, S.; Tweedy, S.; West, S.; Hui, J.; Kearney, B.P. Pharmacokinetic interaction of
ritonavir-boosted elvitegravir and maraviroc. J. Acquir. Immune Defic. Syndr. 2010, 53, 209–214. [CrossRef]
[PubMed]
48. Ponte-Sucre, A. Availability and applications of ATP-binding cassette (ABC) transporter blockers.
Appl. Microbiol. Biotechnol. 2007, 76, 279–286. [CrossRef] [PubMed]
49. Owen, A.; Janneh, O.; Hartkoorn, R.C.; Chandler, B.; Bray, P.G.; Martin, P.; Ward, S.A.; Hart, C.A.; Khoo, S.H.;
Back, D.J. In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with
mefloquine. J. Pharmacol. Exp. Ther. 2005, 314, 1202–1209. [CrossRef] [PubMed]
50. Kruh, G.D.; Belinsky, M.G. The MRP family of drug efflux pumps. Oncogene 2003, 22, 7537–7552. [CrossRef]
[PubMed]
51. Roy, U.; Bulot, C.; Honer zu Bentrup, K.; Mondal, D. Specific increase in MDR1 mediated drug-efflux in
human brain endothelial cells following co-exposure to HIV-1 and saquinavir. PLoS ONE 2013, 8, e75374.
[CrossRef] [PubMed]
52. Perloff, M.D.; von Moltke, L.L.; Greenblatt, D.J. Ritonavir and dexamethasone induce expression of CYP3A
and P-glycoprotein in rats. Xenobiotica 2004, 34, 133–150. [CrossRef] [PubMed]
53. Perloff, M.D.; von Moltke, L.L.; Fahey, J.M.; Greenblatt, D.J. Induction of P-glycoprotein expression and
activity by ritonavir in bovine brain microvessel endothelial cells. J. Pharm. Pharmacol. 2007, 59, 947–953.
[CrossRef] [PubMed]
54. Zastre, J.A.; Chan, G.N.Y.; Ronaldson, P.T.; Ramaswamy, M.; Couraud, P.O.; Romero, I.A.; Weksler, B.;
Bendayan, M.; Bendayan, R. Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain
microvessel endothelial cell line. J. Neurosci. Res. 2009, 87, 1023–1036. [CrossRef] [PubMed]
55. Urquhart, B.L.; Tirona, R.G.; Kim, R.B. Nuclear receptors and the regulation of drug-metabolizing enzymes
and drug transporters: Implications for interindividual variability in response to drugs. J. Clin. Pharmacol.
2007, 47, 566–578. [CrossRef] [PubMed]
56. Bauer, B.; Hartz, A.M.S.; Fricker, G.; Miller, D.S. Pregnane X receptor up-regulation of P-glycoprotein
expression and transport function at the blood-brain barrier. Mol. Pharmacol. 2004, 66, 413–419. [CrossRef]
[PubMed]
57. Bauer, B.; Yang, X.; Hartz, A.M.S.; Olson, E.R.; Zhao, R.; Kalvass, J.C.; Pollack, G.M.; Miller, D.S.
In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through
P-glycoprotein up-regulation. Mol. Pharmacol. 2006, 70, 1212–1219. [CrossRef] [PubMed]
58. Ott, M.; Fricker, G.; Bauer, B. Pregnane X receptor (PXR) regulates P-glycoprotein at the blood-brain barrier:
Functional similarities between pig and human PXR. J. Pharmacol. Exp. Ther. 2009, 329, 141–149. [CrossRef]
[PubMed]
59. Wang, X.; Sykes, D.B.; Miller, D.S. Constitutive androstane receptormediated up-regulation of ATP-driven
xenobiotic efflux transporters at the blood-brain barrier. Mol. Pharmacol. 2010, 78, 376–383. [CrossRef]
[PubMed]
Pharmaceutics 2018, 10, 39 13 of 15
60. Lemmen, J.; Tozakidis, I.E.P.; Bele, P.; Galla, H.J. Constitutive androstane receptor upregulates Abcb1 and
Abcg2 at the blood-brain barrier after CITCO activation. Brain Res. 2013, 1501, 68–80. [CrossRef] [PubMed]
61. Chan, G.N.; Hoque, M.T.; Cummins, C.L.; Bendayan, R. Regulation of P-glycoprotein by orphan nuclear
receptors in human brain microvessel endothelial cells. J. Neurochem. 2011, 118, 163–175. [CrossRef]
[PubMed]
62. Dussault, I.; Lin, M.; Hollister, K.; Wang, E.H.; Synold, T.W.; Forman, B.M. Peptide mimetic HIV protease
inhibitors are ligands for the orphan receptor SXR. J. Biol. Chem. 2001, 276, 33309–33312. [CrossRef] [PubMed]
63. Svärd, J.; Spiers, J.P.; Mulcahy, F.; Hennessy, M. Nuclear receptor mediated induction of CYP450 by
antiretrovirals: Functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in
whites and sub-Saharan Africans. J. Acquir. Immune Defic. Syndr. 2010, 55, 536–549. [CrossRef] [PubMed]
64. Chan, G.N.; Patel, R.; Cummins, C.L.; Bendayan, R. Induction of P-glycoprotein by antiretroviral drugs in
human brain microvessel endothelial cells. Antimicrob. Agents Chemother. 2013, 57, 4481–4488. [CrossRef]
[PubMed]
65. Shukla, S.; Ohnuma, S.; Ambudkar, S.V. Improving cancer chemotherapy with modulators of ABC drug
transporters. Curr. Drug Targets 2011, 12, 621–630. [CrossRef] [PubMed]
66. Gillet, J.P.; Efferth, T.; Remacle, J. Chemotherapy-induced resistance by ATP-binding cassette transporter
genes. Biochim. Biophys. Acta 2007, 1775, 237–262. [CrossRef] [PubMed]
67. Xia, C.Q.; Smith, P.G. Drug efflux transporter and multidrug resistance in acute leukemia: Therapeutic
impact and novel approaches to mediation. Mol. Pharmacol. 2012, 82, 1008–1021. [CrossRef] [PubMed]
68. Begley, D.J. Delivery of therapeutic agents to central nervous system: The problems and the possibilities.
Pharmacol. Ther. 2004, 104, 29–45. [CrossRef] [PubMed]
69. Aller, S.G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell, P.M.; Trinh, Y.T.; Zhang, Q.;
Urbatsch, I.L.; et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding.
Science 2009, 323, 1718–1722. [CrossRef] [PubMed]
70. Namanja, H.A.; Emmert, D.; Hrycyna, C.A.; Chmielewski, J. Homodimers of the antiviral abacavir as
modulators of P-glycoprotein transport in cell culture: Probing tether length. Medchemcomm 2013, 4,
1344–1349. [CrossRef] [PubMed]
71. Dalpiaz, A.; Paganetto, G.; Pavan, B.; Fogagnolo, M.; Medici, A.; Beggiato, S.; Perrone, D. Zidovudine and
ursodeoxycholic acid conjugation: Design of a new prodrug potentially able to bypass the active efflux
transport systems of the central nervous system. Mol. Pharm. 2012, 9, 957–968. [CrossRef] [PubMed]
72. Dalpiaz, A.; Contado, C.; Mari, L.; Perrone, D.; Pavan, B.; Paganetto, G.; Hanuskovà, M.; Vighi, E.; Leo, E.
Development and characterization of PLGA nanoparticles as delivery systems of a prodrug of zidovudine
obtained by its conjugation with ursodeoxycholic acid. Drug Deliv. 2014, 21, 221–1232. [CrossRef] [PubMed]
73. Dalpiaz, A.; Ferraro, L.; Perrone, D.; Leo, E.; Iannuccelli, V.; Pavan, B.; Paganetto, G.; Beggiato, S.; Scalia, S.
Brain uptake of a Zidovudine prodrug after nasal administration of solid lipid microparticles. Mol. Pharm.
2014, 11, 1550–1561. [CrossRef] [PubMed]
74. Zink, M.C. Translational research models and novel adjunctive therapies for neuroAIDS. J. Neuroim. Pharmacol.
2007, 2, 14–19. [CrossRef] [PubMed]
75. Dou, H.; Morehead, J.; Destache, C.J.; Kingsley, J.D.; Shlyakhtenko, L.; Zhou, Y.; Chaubal, M.;
Werling, J.; Kipp, J.; Rabinow, B.E.; et al. Laboratory investigations for the morphologic, pharmacokinetic,
and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology
2007, 358, 148–158. [CrossRef] [PubMed]
76. Gorantla, S.; Dou, H.; Boska, M.; Destache, C.J.; Nelson, J.; Poluektova, L.; Rabinow, B.E.; Gendelman, H.E.;
Mosley, R.L. Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and
nanoformulated drug delivery. J. Leukoc. Biol. 2006, 80, 1165–1174. [CrossRef] [PubMed]
77. Gao, H. Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm. Sin. B
2016, 6, 268–286. [CrossRef] [PubMed]
78. Manfredini, S.; Pavan, B.; Vertuani, S.; Scaglianti, M.; Compagnone, D.; Biondi, C.; Scatturin, A.; Tanganelli, S.;
Ferraro, L.; Prasad, P.; et al. Design, synthesis and activity of ascorbic acid prodrugs of nipecotic, kynurenic
and diclophenamic acids, liable to increase neurotropic activity. J. Med. Chem. 2002, 45, 559–562. [CrossRef]
[PubMed]
79. Illum, L. Is nose-to-brain transport of drugs in man a reality? J. Pharm. Pharmacol. 2004, 56, 3–17. [CrossRef]
[PubMed]
Pharmaceutics 2018, 10, 39 14 of 15
80. Johnson, N.J.; Hanson, L.R.; Frey, W.H. Trigeminal pathways deliver a low molecular weight drug from the
nose to the brain and orofacial structures. Mol. Pharm. 2010, 7, 884–893. [CrossRef] [PubMed]
81. Casettari, L.; Illum, L. Chitosan in nasal delivery systems for therapeutic drugs. J. Control. Release 2014, 190,
189–200. [CrossRef] [PubMed]
82. Hanson, L.R.; Frey, W.H., 2nd. Strategies for intranasal delivery of therapeutics for the prevention and
treatment of neuroAIDS. J. Neuroimmune Pharmacol. 2007, 2, 81–86. [CrossRef] [PubMed]
83. Boivin, N.; Sergerie, Y.; Rivest, S.; Boivin, G. Effect of pretreatment with toll-like receptor agonists in a mouse
model of herpes simplex virus type 1 encephalitis. J. Infect. Dis. 2008, 198, 664–672. [CrossRef] [PubMed]
84. Elia, G.; Belloli, C.; Cirone, F.; Lucente, M.S.; Caruso, M.; Martella, V.; Decaro, N.; Buonavoglia, C.; Ormas, P.
In vitro efficacy of ribavirin against canine distemper virus. Antivir. Res. 2008, 77, 108–113. [CrossRef]
[PubMed]
85. Colombo, G.; Lorenzini, L.; Zironi, E.; Galligioni, V.; Sonvico, F.; Balducci, A.G.; Pagliuca, G.; Giuliani, A.;
Calzà, L.; Scagliarini, A. Brain distribution of ribavirin after intranasal administration. Antivir. Res. 2011, 92,
408–414. [CrossRef] [PubMed]
86. Giuliani, A.; Balducci, A.G.; Zironi, E.; Colombo, G.; Bortolotti, F.; Lorenzini, L.; Galligioni, V.; Pagliuca, G.;
Scagliarini, A.; Calzà, L.; et al. In vivo nose-to-brain delivery of the hydrophilic antiviral ribavirin by
microparticle agglomerates. Drug Deliv. 2018, 25, 376–387. [CrossRef] [PubMed]
87. Mistry, A.; Stolnik, S.; Illum, L. Nanoparticles for direct nose-to-brain delivery of drugs. Int. J. Pharm.
2009, 379, 146–157. [CrossRef] [PubMed]
88. Hoekman, J.D.; Ho, R.J. Effects of localized hydrophilic mannitol and hydrophobic nelfinavir administration
targeted to olfactory epithelium on brain distribution. AAPS PharmSciTech. 2011, 12, 534–543. [CrossRef]
[PubMed]
89. Stutzle, M.; Flamm, J.; Carle, S.; Schindowski, K. Nose-to-Brain delivery of insulin for Alzheimer’s disease.
ADMET DMPK 2015, 3, 190–202. [CrossRef]
90. Djupesland, P.G.; Messina, J.C.; Mahmoud, R.A. The nasal approach to delivering treatment for brain
diseases: An anatomic, physiologic, and delivery technology overview. Ther. Deliv. 2014, 5, 709–733.
[CrossRef] [PubMed]
91. Qu, W.; Li, N.; Yu, R.; Zuo, W.; Fu, T.; Fei, W.; Hou, Y.; Liu, Y.; Yang, J. Cationic DDA/TDB liposome
as a mucosal vaccine adjuvant for uptake by dendritic cells in vitro induces potent humoural immunity.
Artif. Cells Nanomed. Biotechnol. 2018, 15, 1–9. [CrossRef] [PubMed]
92. Hulisz, D. Efficacy of zinc against common cold viruses: An overview. J. Am. Pharm. Assoc. 2004, 44, 594–603.
[CrossRef]
93. Seremeta, K.P.; Chiappetta, D.A.; Sosnik, A. Poly(ε-caprolactone), Eudragit® RS 100 and poly(ε-
caprolactone)/Eudragit® RS 100 blend submicron particles for the sustained release of the antiretroviral
efavirenz. Colloids Surf. B Biointerfaces. 2013, 102, 441–449. [CrossRef] [PubMed]
94. Lehr, C.M.; Bouwstra, J.A.; Schacht, E.H.; Junginger, H.E. In vitro evaluation of mucoadhesive properties of
chitosan and some other natural polymers. Int. J. Pharm. 1992, 78, 43–48. [CrossRef]
95. Nazar, H.; Fatouros, D.G.; van der Merwe, S.M.; Bouropoulos, N.; Avgouropoulos, G.; Tsibouklis, J.; Roldo, M.
Thermosensitive hydrogels for nasal drug delivery: The formulation and characterisation of systems based
on N-trimethyl chitosan chloride. Eur. J. Pharm. Biopharm. 2011, 77, 225–232. [CrossRef] [PubMed]
96. Nakamura, K.; Maitani, Y.; Lowman, A.M.; Takayama, K.; Peppas, N.A.; Nagai, T. Uptake and release
of budesonide from mucoadhesive, pH-sensitive copolymers and their application to nasal delivery.
J. Control. Release 1999, 61, 329–335. [CrossRef]
97. Soane, R.J.; Hinchcliffe, M.; Davis, S.S.; Illum, L. Clearance characteristics of chitosan based formulations in
the sheep nasal cavity. Int. J. Pharm. 2001, 217, 183–191. [CrossRef]
98. Zaki, N.M.; Awad, G.A.; Mortada, N.D.; Abd Elhady, S.S. Enhanced bioavailability of metoclopramide HCl
by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary
transport properties. Eur. J. Pharm. Sci. 2007, 32, 296–307. [CrossRef] [PubMed]
99. Lungare, S.; Bowen, J.; Badhan, R. Development and Evaluation of a Novel Intranasal Spray for the Delivery
of Amantadine. J. Pharm. Sci. 2016, 105, 1209–1220. [CrossRef] [PubMed]
100. Paul, W.; Sharma, C.P. Chitosan, a drug carrier for the 21st century: A review. S.T.P. Pharm. Sci. 2000, 10,
5–22.
Pharmaceutics 2018, 10, 39 15 of 15
101. Vllasaliu, D.; Exposito-Harris, R.; Heras, A.; Casettari, L.; Garnett, M.; Illum, L.; Stolnik, S. Tight junction
modulation by chitosan nanoparticles: Comparison with chitosan solution. Int. J. Pharm. 2010, 400, 183–193.
[CrossRef] [PubMed]
102. Bertram, U.; Bodmeier, R. In situ gelling, bioadhesive nasal inserts for extended drug delivery: In vitro
characterization of a new nasal dosage form. Eur. J. Pharm. Sci. 2006, 27, 62–71. [CrossRef] [PubMed]
103. Roos, A.; Creton, C.; Novikov, M.B.; Feldstein, M.M. Viscoelasticity and tack of poly(vinyl
pyrrolidone)–poly(ethylene glycol) blends. J. Polym. Sci. Part B Polym. Phys. 2002, 40, 2395–2409. [CrossRef]
104. Alsarra, I.A.; Hamed, A.Y.; Mahrous, G.M.; El Maghraby, G.M.; Al-Robayan, A.A.; Alanazi, F.K.
Mucoadhesive polymeric hydrogels for nasal delivery of acyclovir. Drug Dev. Ind. Pharm. 2009, 35,
352–362. [CrossRef] [PubMed]
105. Krishan, M.; Gudelsky, G.A.; Desai, P.B.; Genter, M.B. Manipulation of olfactory tight junctions using
papaverine to enhance intranasal delivery of gemcitabine to the brain. Drug Deliv. 2014, 21, 8–16. [CrossRef]
[PubMed]
106. Mahajan, H.S.; Mahajan, M.S.; Nerkar, P.P.; Agrawal, A. Nanoemulsion-based intranasal drug delivery
system of saquinavir mesylate for brain targeting. Drug Deliv. 2014, 21, 148–154. [CrossRef] [PubMed]
107. Pardridge, W.M. Blood-brain barrier drug targeting: The future of brain drug development. Mol. Interv.
2003, 3, 90–105. [CrossRef] [PubMed]
108. Wong, S.L.; Van Belle, K.; Sawchuk, R.J. Distributional transport kinetics of zidovudine between plasma and
brain extracellular fluid/cerebrospinal fluid in the rabbit: Investigation of the inhibitory effect of probenecid
utilizing microdialysis. J. Pharmacol. Exp. Ther. 1993, 264, 899–909. [PubMed]
109. Takasawa, K.; Terasaki, T.; Suzuki, H.; Sugiyama, Y. In vivo evidence for carrier-mediated efflux
transport of 3′-azido-3′-deoxythymidine and 2′, 3′-dideoxyinosine across the blood-brain barrier via a
probenecid-sensitive transport system. J. Pharmacol. Exp. Ther. 1997, 281, 369–375. [PubMed]
110. Wang, Y.; Sawchuk, R.J. Zidovudine transport in the rabbit brain during intravenous and
intracerebroventricular infusion. J. Pharm. Sci. 1995, 7, 871–876. [CrossRef]
111. Wong, S.L.; Wang, Y.; Sawchuk, R.J. Analysis of zidovudine distribution to specific regions in rabbit brain
using microdialysis. Pharm. Res. 1992, 9, 332–338. [CrossRef] [PubMed]
112. Cunningham, A.L.; Naif, H.; Saksena, N.; Lynch, G.; Chang, J.; Li, S.; Jozwiak, R.; Alali, M.; Wang, B.; Fear, W.;
et al. HIV infection of macrophages and pathogenesis of AIDS dementia complex: Interaction of the host cell
and viral genotype. J. Leukocyte Biol. 1997, 62, 117–125. [CrossRef] [PubMed]
113. Ghersi-Egea, J.F.; Finnegan, W.; Chen, J.L.; Fenstermacher, J.D. Rapid distribution of intraventricularly
administered sucrose into cerebrospinal fluid cisterns via subarachnoid velae in rat. Neuroscience 1996, 75,
1271–1288. [CrossRef]
114. Seki, T.; Sato, N.; Hasegawa, T.; Kawaguchi, T.; Juni, K. Nasal absorption of zidovudine and its transport to
cerebrospinal fluid in rats. Pharm. Bull. 1994, 17, 1135–1137. [CrossRef]
115. Gill, P.S.; Rarick, M.; Brynes, R.K.; Causey, D.; Loureiro, C.; Levine, A. Azidothymidine associated with bone
marrow failure in the acquired immunodeficiency syndrome (AIDS). Ann. Int. Med. 1987, 107, 502–505.
[CrossRef] [PubMed]
116. Ved, P.M.; Kim, K. Poly(ethylene oxide/propylene oxide) copolymer thermo-reversible gelling system for
the enhancement of intranasal zidovudine delivery to the brain. Int. J. Pharm. 2011, 411, 1–9. [CrossRef]
[PubMed]
117. Al-Ghananeem, A.M.; Smith, M.; Coronel, M.L.; Tran, H. Advances in brain targeting and drug delivery of
anti-HIV therapeutic agents. Expert Opin. Drug Deliv. 2013, 10, 973–985. [CrossRef] [PubMed]
118. Mamik, M.K.; Asahchop, E.L.; Chan, W.F.; Zhu, Y.; Branton, W.G.; McKenzie, B.A.; Cohen, E.A.; Power, C.
Insulin treatment prevents neuroinflammation and neuronal injury with restored neurobehavioral function
in models of HIV/AIDS neurodegeneration. J. Neurosci. 2016, 36, 10683–10695. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
